Fortfahren mit
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
Ansicht ändern
| Größe/SKU | Verfügbarkeit | Preis |
|---|---|---|
10 mg | Warenkorb auf Verfügbarkeit prüfen | € 124,00 |
Über diesen Artikel
NACRES:
NA.77
UNSPSC Code:
12352200
Assay:
≥98% (HPLC)
Form:
powder
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltenQuality Segment
assay
≥98% (HPLC)
form
powder
solubility
DMSO: 100 mg/mL, H2O: 15 mg/mL
storage temp.
2-8°C
General description
TAS-102 is a combination of two active ingredients: trifluridine (TFT), a nucleoside analog, and tipiracil (TPI), a thymidine phosphorylase inhibitor in a 1.0:0.5 molar ratio (TFT:TPI).1 TFT is the active antitumor component of TAS-102, its monophosphate form inhibits thymidylate synthase, an enzyme that plays a main role in DNA synthesis, and its triphosphate form is incorporated into DNA in tumor cells resulting in DNA dysfunction. TPI increases the bioavailability of TFT that is rapidly degraded to its inactive form by thymidine phosphorylase in the intestines and liver. The formulation presents a double targeted due to the cytotoxic effect of TFT, which is enhanced by TPI, while TPI also exerts antiangiogenic effects by inhibiting thymidine phosphorylase.2 TAS 102 inhibits KM20C colon cancer xenograft growth by 70.5% when was orally administered twice daily at a dose of 150 mg/kg for 14 days.3 TAS-102 has great potential to improve the treatment of malignancies when combined with other angiostatic or cytotoxic agents. A combination of TAS-102 and Avastin, an antineoplastic agent, was found to increase chemotherapeutic efficacy against colorectal cancer xenograft, compared with that for either drug alone.4
Biochem/physiol Actions
Anti cancer, Anti angiogenic
Other Notes
Solubility:DMSO 100 mg/mL; water 15mg/ml
TAS-102 is a mixture of 2 components. In order to maintain the original ratio between the components, the entire content of vial needs to be solubilized.
TAS-102 is a mixture of 2 components. In order to maintain the original ratio between the components, the entire content of vial needs to be solubilized.
1 of 1
Dieser Artikel | ||
|---|---|---|
| description ≥98% (HPLC) | description British Pharmacopoeia (BP) Reference Standard | description United States Pharmacopeia (USP) Reference Standard |
| assay ≥98% (HPLC) | assay - | assay - |
| form powder | form solid | form - |
| Quality Level 100 | Quality Level - | Quality Level - |
| storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C |
| solubility DMSO: 100 mg/mL, H2O: 15 mg/mL | solubility - | solubility - |
Signalwort
Warning
Gefahrencodes
Sicherheitshinweise
Hazard Classifications
Carc. 2 - Muta. 2 - Repr. 2
Lagerklasse
11 - Combustible Solids
Was ist los?
WGK 3
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.


